Sage Journals: Discover world-class research

Abstract

Background:

It is estimated that 1–2.5 million U.S. women use compounded bioidentical menopausal hormone therapy (MHT). However, the proportion of American physicians prescribing compounded bioidentical hormones remains unknown. This study aims to evaluate obstetrician–gynecologists' (OB/GYNs) and family medicine physicians' decisions reflected in prescribing practices of MHT in Kansas, and level of agreement with the American College of Obstetricians and Gynecologists (ACOG) recommendations.

Methods:

An Internet-based 38-item survey was electronically disseminated to OB/GYNs and family medicine physicians identified through the Kansas State Board of Healing Arts licensure list.

Results:

Out of 1349 physicians contacted, 164 (12.2%) responded to the survey. There were 128 (9.5%) responses included in the final analysis. In the past year, 96.1% (123/128) of respondents prescribed conventional MHT, 93.0% (119/128) prescribed Food and Drug Administration (FDA)-approved bioidentical MHT, and 66.1% (84/127) prescribed compounded bioidentical MHT. Of factors influencing MHT-prescribing practices, FDA regulation was not important to 16.7% (21/126) of physicians, whereas customization was important to 68.5% (87/127). There was a significant difference between specialties, 37.7% of OB/GYNs compared with 56.9% of family medicine physicians, regarding the ACOG statement that “patients should be counseled that conventional MHT is more appropriate than compounded preparations” (p = 0.031). Respondents disagreed with ACOG regarding the statements that “the practice of compounding makes it difficult to identify the active agent responsible for various effects” (41.0% of OB/GYNs and 34.8% of family medicine physicians) and “the practice of custom blending commercially available drug products lacks both a strong biological rationale and medical evidence for effectiveness” (36.1% of OB/GYNs and 37.9% of family medicine physicians).

Conclusions:

Prescribing practices for MHT vary between specialties. This study identifies a meaningful level of disagreement with ACOG recommendations regarding prescription of compounded rather than FDA-approved MHT. Further research is needed to better understand this level of discordance.

Get full access to this article

View all access options for this article.

References

American College of Obstetricians and Gynecologists. Committee opinion No. 532: Compounded bioidentical menopausal hormone therapy. Obstet Gynecol, 2012; 120(Pt 1):411–415.

Steinkellner

, Denison

, Eldridge

, Lenzi

, Chen

, Bowlin

. A decade of postmenopausal hormone therapy prescribing in the United States: Long-term effects of the Women's Health Initiative. Menopause, 2012; 19:616–621.

Wassertheil-Smoller

, Hendrix

, Limacher

, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. JAMA, 2003; 289:2673–2684.

Rossouw

, Anderson

, Prentice

, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002; 288:321–333.

Pinkerton

. What are the concerns about custom-compounded “bioidentical” hormone therapy?. Menopause, 2014; 21:1298–1300.

U.S. Food and Drug Administration. 2006. Limited FDA survey of compounded drug products. U.S. Food and Drug Administration, 2006. Updated May 5, 2016. Available at: www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm204237.htm Accessed May 31, 2016 .

Files

, Ko

, Pruthi

. Bioidentical hormone therapy. Mayo Clin Proc, 2011; 86:673–680, quiz 80.

Boothby

, Doering

. Bioidentical hormone therapy: A panacea that lacks supportive evidence. Curr Opin Obstet Gynecol, 2008; 20:400–407.

Stefanick

. Estrogens and progestins: Background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med, 2005; 118(Suppl 12B):64–73.

10.

Pinkerton

, Constantine

. Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: Results of a pharmacy survey. Menopause, 2016; 23:359–367.

11.

Pinkerton

, Santoro

. Compounded bioidentical hormone therapy: Identifying use trends and knowledge gaps among US women. Menopause, 2015; 22:926–936.

12.

Gass

, Stuenkel

, Utian

, LaCroix

, Liu

, Shifren

. Use of compounded hormone therapy in the United States: Report of The North American Menopause Society Survey. Menopause, 2015; 22:1276–1284.

13.

Constantine

, Archer

, Graham

, Bernick

, Mirkin

. Prescribing of FDA-approved and compounded hormone therapy differs by specialty. Menopause, 2016; 23:1075–1082.

14.

Iftikhar

, Shuster

, Johnson

, Jenkins

, Wahner-Roedler

. Use of bioidentical compounded hormones for menopausal concerns: Cross-sectional survey in an academic menopause center. J Womens Health (Larchmt), 2011; 20:559–565.

15.

U.S. Food and Drug Administration. The special risks of pharmacy compounding. Updated February 22, 2016. Available at: https://www.pharmwatch.org/reports/compounding_risks.pdf Accessed March 16, 2018 .

16.

U.S. Food and Drug Administration. Bio-identicals: sorting myths from facts. Updated August 28, 2012. Available at: https://www.catawbawomenscenter.com/images/MenopauseFDAStatement.pdf Accessed March 16, 2018 .

17.

North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 2017; 24:728–753.

18.

Santoro

, Braunstein

, Butts

, Martin

, McDermott

, Pinkerton

. Compounded bioidentical hormones in endocrinology practice: An endocrine society scientific statement. J Clin Endocrinol Metab, 2016; 101:1318–1343.

19.

U.S. Food and Drug Administration. Report: Limited FDA survey of compounded drug products. 2001. Updated May 5, 2016. Available at: www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm155725.htm Accessed June 18, 2016 .

20.

U.S. Food and Drug Administration. Registered outsourcing facilities. 2017. Updated October 20, 2017. Available at: www.fda.gov/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/ucm378645.htm Accessed November 3, 2017 .

21.

Shehab

, Brown

, Kallen

, Perz

. U.S. compounding pharmacy-related outbreaks, 2001–2013: Public health and patient safety lessons learned. J Patient Saf, 2015. [Epub ahead of print]; DOI:10.1097/PTS.0000000000000188.

22.

Staes

, Jacobs

, Mayer

, Allen

. Description of outbreaks of health-care-associated infections related to compounding pharmacies, 2000–2012. Am J Health Syst, 2013; 70:1301–1312.

23.

Sellers

, Utian

. Pharmacy compounding primer for physicians: Prescriber beware. Drugs, 2012; 72:2043–2050.

24.

Davis

, Batur

, Thacker

. Risks and effectiveness of compounded bioidentical hormone therapy: A case series. J Womens Health (Larchmt), 2014; 23:642–648.

25.

Sood

, Warndahl

, Schroeder

, et al. Bioidentical compounded hormones: A pharmacokinetic evaluation in a randomized clinical trial. Maturitas, 2013; 74:375–382.

26.

Dezman

, Gersak

. Two case of atypical endometrial hyperplasia associated with “bioidentical” hormone replacement therapy: IGCS-0084 uterine cancer, including sarcoma. Int J Gynecol Cancer, 2015; 25(Suppl 1):71.

Prescribing Bioidentical Menopausal Hormone Therapy: A Survey of Physician Views and Practices

Abstract

Background:

Methods:

Results:

Conclusions:

Get full access to this article

References